Bioavailability
File: ORNIDAZOLE
Sinem Y. HIZARCIOÐLU*, Zeynep AY*, Mine ÖZYAZICI*o
* Ege University, Faculty of Pharmacy, Department of Pharmaceutical
Technology, 35100 Bornova, Ýzmir-TURKEY.
oCorresponding Author
Summary
Ornidazole is a 5-nitroimidazole derivative drug which has
antimicrobial action. It is used in the treatment of protozoal
infecti-ons, and also in the treatment and prophylaxis of
anaerobic bacterial infections. The mean ornidazole elimination
half-life is 12 hours, significantly longer than that of
some nitroimidazole derivatives. This is a particular advantage
for reducing the dosage frequency and duration of therapy
in many of the relevant clinical infections. Ornidazole
acts by damage of DNA strands or inhibition of their synthesis.
It is widely distributed in body tissues and fluids, including
the cerebrospinal fluid. Ornidazole is metabolized in the
liver. It is excreted in the urine, mainly as conjugates
and metabolites, and to a lesser extent in the feces and
bile. Ornidazole is administered orally, vaginally, or intravenously.
In this review, physicochemical, pharmacological and pharmacokinetic
properties in addition to bioavailability of ornidazole
are discussed.
Key Words :
Ornidazole, bioavailability, pharmacokinetics,
stability, physicochemical properties.
|
